Barry Berger Discusses Cologuard

Video

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Berger says the test is straightforward because it give a positive or negative answer, which is concluded by examining DNA and fecal hemoglobin in the sample that the patients provide. However, patients should know that Cologuard does not use inherited DNA for screening, but instead looks at changes in DNA that are a result of undergoing carcinogenisis.

Recent Videos
a man wearing a suit and tie in front of a green screen with the ONN logo
a woman sitting in front of a CURE Background with a black and floral top
Related Content
dark blue background with a white outline indicating the gastrointestinal tract

Camrelizumab Plus Chemo Boosts Response in Gastric/GEJ Cancer

Ariana Pelosci
January 26th 2025
Article

The phase 2 FDZL-001 trial showed high overall survival and progression-free survival rates with camrelizumab plus Nab-POF in patients with gastric/GEJ cancer.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

yellow background with a white outline indicating the pancreas

Liposomal Irinotecan, Oxaliplatin Dose Reduction May Not Affect Survival in Metastatic PDAC

Jax DiEugenio
January 25th 2025
Article

Analysis of the NAPOLI 3 trial showed that lower doses of liposomal irinotecan or oxaliplatin did not reduce survival in patients with pancreatic ductal adenocarcinoma.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Simple illustration of the gastrointestinal track on a light blue background

Cabozantinib Lengthens PFS for Extrapancreatic NETs of GI Origin

Megan Hollasch
January 24th 2025
Article

Cabozantinib prolonged PFS compared to placebo for patients with extrapancreatic NETs starting in the GI tract in a subgroup analysis of the CABINET trial.

yellow background with a white outline indicating the GI tract

Preoperative Sintilimab with Chemoradiotherapy Boosts Response Rates in Resectable Esophageal Cancer

Chris Ryan
January 24th 2025
Article

Preoperative sintilimab with chemoradiotherapy boosted pathological complete response rates in patients with resectable, locally advanced esophageal squamous cell carcinoma.